Misiunea noastră este să ajutăm oamenii să vadă mai clar și să își îmbunătățească calitatea vieții.

Tehnologia noastră s-a dovedit clinic că îmbunătățește vederea într-o varietate de afecțiuni ale vederii și este autorizată de FDA pentru ambliopia peste vârsta de 9 ani. RevitalVision îmbunătățește procesarea vizuală a creierului, permițând îmbunătățiri semnificative ale vederii dincolo de îngrijirea oftalmologică standard, făcând cu adevărat o diferență

Faceți cunoștință cu echipa

Yair Yahav
Founder & CEO
Yogev Shamay
Co-founder & CTO
Yonina Thee
Clinical Specialist
Inbal Sasson
Marketing Director

Consiliul de administrație

Simon Kan
Director
Yair Yahav
Director
Susan Benton
Director

Consiliul consultativ

Prof. Richard W. Hertle (MD)
Scientific & Clinical Advisor
Prof. Ramesh

Kekunnaya (MD)
Scientific & Clinical Advisor
Dr. Sarah Maling (MD)
Advisory Board
Mike Turner
Advisory Board
Prof. Yair Morad (MD)
Scientific & Clinical Advisor

Latest News and Events

News icon

01/08/2020

WSPOS – World Wide Webinar on Amblyopia – Sponsored by REVITALVISION

World Society of Pediatric Ophthalmology and Strabismus
World Society of pediatric ophtamology and strabismus banner
News icon

21-24 April 2021

REVITALVISION will participate at the upcoming 41st ESA (EUROPEAN STRABISMOLOGICAL ASSOCIATION)

Meeting in PARIS 21th /24th April 2021

Link to article
ESA
News icon

2020

A New Adult Amblyopia study presented at AIOS 2020 (All India Ophthalmology Society)

meeting 2020 confirming again the efficacy of RevitalVision in improving vision in adult amblyopia

Download ppt
AIOS 2020
News icon

7 October

REVITALVISION will participate at the upcoming AAOPT (AMERICAN ACADEMY of OOPTOMETRY)

Meeting in Nashville, TN, USA 7-10 October

Link to article
AAOPT
News icon

2020

Tel Aviv Medical Center is recruiting Age related Macular Degeneration patients for a REVITALVISION clinical study

A Proof-of-Concept, Prospective, Open label, Randomized Clinical Study Evaluating RevitalVision® Therapy for Improving Best Corrected Visual Acuity (BCVA) and Contrast Sensitivity Function (CSF) in Patients Suffering from stabler Age related Macular Degeneration (AMD)

Logo of Tel Aviv medical center
1 5 6 7